Statins Against Bushfire Smoke

NCT07462715 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-10

No results posted yet for this study

Summary

The goal of this clinical trial is to test whether statins can protect the heart and brain from the biological stress and inflammatory responses caused by breathing bushfire smoke in healthy adult volunteers aged 18-64 years. The main questions it aims to answer are:

1. Does short-term statin use (2 days) reduce bushfire smoke-induced changes in heart rate variability, blood pressure, arterial stiffness, inflammation and oxidative stress markers, and cognitive function?
2. Does long-term statin use (≥12 months) reduce bushfire smoke-induced changes in heart rate variability, blood pressure, arterial stiffness, inflammation and oxidative stress markers, and cognitive function?

The study includes two streams:

Stream 1:short-term statin use (2 days) where participants receive either statin tablets (80mg atorvastatin) or placebo; Stream 2: long-term statin use (≥12 months) where participants include those already taking statins (≥12 months) with statin-naïve individuals.

Participants will:

* Attend two 3½-hour visits to a Climate Hut, which are approximately 4 weeks apart, where they will spend 2 hours exposed to either filtered air or simulated dilute bushfire smoke (average particulate matter (PM2.5) concentration of 300μg/m\^3) in randomised order;
* Have continuous heart monitoring with ECG leads and blood pressure checks every 15 minutes during each visit
* Provide urine, saliva, and nose swab samples before and after each exposure, plus follow-up samples the next morning
* Complete cognitive tests (reaction time, memory tasks) and postural balance measurements during exposure
* Complete questionnaires about anxiety levels, symptoms, diet, and health status
* Have blood samples collected and pulse wave velocity measurements (assessing arterial stiffness) immediately after each exposure session.

Potential risks include time commitment, muscle pain from statins, eye irritation or throat discomfort from smoke exposure, and minor discomfort from blood collection.

Conditions

  • Healthy Adults

Interventions

DRUG

Atorvastatin

Statin treatment is being investigated to see if it will modify subclinical adverse cardiovascular effects of bushfire smoke. Controlled dilute bushfire smoke is delivered on two occasions 4 weeks apart in a specialist facility. It is order randomised and masked.

DRUG

Placebo

Identical placebo tablets to the atorvastatin tablets used in the intervention group

Sponsors & Collaborators

  • Menzies Institute for Medical Research

    lead OTHER

Principal Investigators

  • Fay Johnston, MD, PhD · Menzies Institute for Medical Research, University of Tasmania

  • Lieke Scheepers, PhD · Menzies Institute for Medical Research

  • Quan Huynh, MD, PhD · Menzies Institute for Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-06-30
Completion
2028-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462715 on ClinicalTrials.gov